Tue, Jul 22, 2014, 10:37 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Cytokinetics, Incorporated Message Board

  • hawk25702 hawk25702 Jun 27, 2013 7:57 AM Flag

    what I'd like to know is what the 'triggers' are for CYTK to receive milestone payments......

    could one trigger possibly be if positive results are announced at the September 3rd meeting? I mean, it has been said by Blum that most triggers are pre-approval by the FDA. Fifty million from the Japan deal is to come pre-commercialization so I'd assume that part is after the FDA nod of approval....with over $600 million in potential milestones (actually a bit more), it just makes me wonder what the first trigger will be.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "like wonder woman"... well said big fella... we definitely wont know what the triggers are, but i bet if you see big upswings leading into the presentation in sept (i'm talking real big) then you can bet a trigger will have something to do with the presentation then as insiders will be driving those upswings... but who knows.

      big fella, i think the reverse split was a play on the company's part showing Amgen that they have no fears (and no concern on what shareholders think) in raising the capital to increase their % of OM royalties. so if they ARE being set up to be bought out, then this is just a way of upping their ante and showing Amgen or whoever that they better bring some dough to the table. thoughts?

      • 1 Reply to stacking_and_chasing
      • I'm pretty sure Amgen had much to do with CYTK striking a collaboration deal with Astel. The way this thing seems to be setting up is that OM gets thru whatever key stage Amgen is targeting and then go for buyout of Astel and CY and thus Amgen gets a subsidary in Japan with a blockbuster drug to sell to both the #1 and #2 markets in the world.......question is, what will CYTK do.

    • i wish i knew hawk. cant count how many times blum has been asked that question and he just deflects it like wonder woman. my guess would be they could earn milestones at the completion of phase 2, start of phase 3, acceptance of nda, fda approval. if things play out, the company could earn around a billion dollars in payments over the next few years. thats a lot of cabbage!

      another looming question is... how much is the company going to contribute to the om phase 3 trial and when do they have to pay? another thing to think about is, if they are being set up to be bought out, then what would be the point of funding a % of phase 3? it wouldnt matter in the end.

      • 2 Replies to thebigfella1234
      • either way, guys, i think we can all agree... we stand to make some good money here as we're all in it long and averaged down pretty well (at least i'm assuming thats both of yall's positions)... i just put in another buy order for any dip today... though it seems the additional coverage and some increased price targets has this looking like a green day

        did either of yall see Cramer's response to CYTK last night? i dont put too much weight into his analysis but i know a lot of people do... he had no clue who CYTK was as he didnt cover it as $1 stock, but now that its $10 he was ready to do his DD. hopefully he does so and feels the way we do and shouts it from the mountain tops to get his followers in the game.

      • lots of questions for sure...if one trigger is completion of phase 2 then CYTK should be flush with cash entering phase 3 so guessing it would be rather easy at that point for CYTK to pony up some more for a bigger piece of the OM pie.....meanwhile, like you say, Amgen may have other plans such as trying to buyout CYTK before entering phase 3 or somewhere early in that process. If I had control of the Amgen checkbook then I think the most prudent and least costly approach for them would certainly be to buyout CY....going to get real interesting as we move forward

4.34-0.08(-1.81%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.